Streetbeat News

Analyst Ratings

SLG

Over the past 3 months, 11 analysts have published their opinion on SL Green Realty (NYSE:SLG) stock. The average price target for SLG has increased by 16.54% from the previous average price target of $29.56 to $34.45. The ratings include 2 bullish, 2 somewhat bullish, 5 indifferent, 1 somewhat bearish, and 1 bearish.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 2:00 pm

ABNB

Airbnb's (NYSE:ABNB) short percent of float has fallen 13.49% since its last report, indicating a more bullish sentiment towards the stock. The company has 20.69 million shares sold short, which is 4.94% of all regular shares available for trading. Compared to its peers, Airbnb has less short interest as a percentage of float, with the average being 6.38%.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 2:00 pm

TARS

Tarsus Pharmaceuticals (NASDAQ:TARS) has received predominantly bullish ratings from analysts in the last quarter, with 6 bullish and 1 somewhat bullish ratings. The company's average 12-month price target has increased by 2.93% from $44.00 to $45.29.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 2:00 pm

CRM

Salesforce's (NYSE:CRM) short percent of float has decreased by 3.75% since its last report, with 7.28 million shares sold short, representing 0.77% of all regular shares available for trading. This decrease in short interest could indicate a more bullish market sentiment towards Salesforce. Compared to its peers, Salesforce has less short interest as a percentage of float, with an average of 3.31%.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 2:00 pm

TTC

Analysts have provided mixed ratings for Toro (NYSE:TTC) in the last quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for Toro is $102.75, a decrease of 10.65% from the previous average price target of $115.00.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 2:00 pm

AZN

DSKYF

DSNKY

AstraZeneca and Daiichi Sankyo released promising initial results from three trials related to lung cancer treatments. The TROPION-Lung04 phase 1b trial showed encouraging responses and no new safety signals for datopotamab deruxtecan in combination with durvalumab, with or without carboplatin. The FLAURA2 Phase 3 trial showed that Tagrisso in combination with chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone. The DESTINY-Lung02 Phase 2 trial showed that Enhertu demonstrated strong and durable tumor responses.

Portfolio Pulse from Vandana Singh

September 11, 2023 | 1:59 pm

FMC

Morgan Stanley analyst Vincent Andrews has maintained an Overweight rating on FMC (NYSE:FMC) but lowered the price target from $110 to $100.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 1:59 pm

BKR

Piper Sandler analyst Luke Lemoine maintains an Overweight rating on Baker Hughes (NASDAQ:BKR) and raises the price target from $43 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 1:58 pm

BUR

B. Riley Securities analyst Matt Howlett maintains a Buy rating on Burford Capital (NYSE:BUR) and raises the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 1:58 pm

HAL

Piper Sandler analyst Luke Lemoine has maintained an Overweight rating on Halliburton (NYSE:HAL) and raised the price target from $46 to $56.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 1:57 pm